These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25700939)

  • 1. Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells.
    Rohilla M; Bal A; Singh G; Joshi K
    Clin Breast Cancer; 2015 Oct; 15(5):335-42. PubMed ID: 25700939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
    Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
    J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.
    Sailer V; Lüders C; Kuhn W; Pelzer V; Kristiansen G
    Virchows Arch; 2015 Jul; 467(1):67-70. PubMed ID: 25850754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphologic, molecular and microenvironment factors associated with stromal invasion in breast ductal carcinoma in situ: Role of myoepithelial cells.
    Aguiar FN; Cirqueira CS; Bacchi CE; Carvalho FM
    Breast Dis; 2015; 35(4):249-52. PubMed ID: 26397772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myoepithelial cells in lobular carcinoma in situ: distribution and immunophenotype.
    Wang Y; Jindal S; Martel M; Wu Y; Schedin P; Troxell M
    Hum Pathol; 2016 Sep; 55():126-34. PubMed ID: 27195907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
    Dabbs DJ; Chivukula M; Carter G; Bhargava R
    Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
    Hilson JB; Schnitt SJ; Collins LC
    Am J Surg Pathol; 2009 Feb; 33(2):227-32. PubMed ID: 18936688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers.
    Zhang RR; Man YG; Vang R; Saenger JS; Barner R; Wheeler DT; Liang CY; Vinh TN; Bratthauer GL
    Breast Cancer Res; 2003; 5(5):R151-6. PubMed ID: 12927046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
    Werling RW; Hwang H; Yaziji H; Gown AM
    Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?
    Schorr MC; Pedrini JL; Savaris RF; Zettler CG
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma.
    Umekita Y; Yoshida H
    Histopathology; 2003 Jun; 42(6):541-5. PubMed ID: 12786889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study.
    Giardina C; Serio G; Lepore G; Lettini T; Dalena AM; Pennella A; D'Eredità G; Valente T; Ricco R
    J Exp Clin Cancer Res; 2003 Jun; 22(2):279-88. PubMed ID: 12866579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
    Paredes J; Lopes N; Milanezi F; Schmitt FC
    Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma.
    Shamloula MM; El-Shorbagy SH; Saied EM
    J Egypt Natl Canc Inst; 2007 Sep; 19(3):202-10. PubMed ID: 19190693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
    Wan D; Zhang Y; Yu Q; Li F; Zhuo J
    Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mean nuclear area and metallothionein expression in ductal breast tumors: correlation with estrogen receptor status.
    El Sharkawy SL; Farrag AR
    Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):108-12. PubMed ID: 18227734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of heterogeneity in breast cancer immunophenotype at ductal carcinoma
    Rohilla M; Bal A; Singh G; Joshi K
    J Cancer Res Ther; 2016; 12(4):1249-1256. PubMed ID: 28169235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.